-
Dermatology Online Journal Aug 2019Topical corticosteroids are available in many vehicles. However, patients' preference for vehicles are variable and could be tailored to maximize patient adherence.... (Review)
Review
BACKGROUND
Topical corticosteroids are available in many vehicles. However, patients' preference for vehicles are variable and could be tailored to maximize patient adherence. Spray vehicles may offer, convenience, and strong efficacy.
METHODS
A literature review was conducted using keywords: clobetasol, desoximetasone, betamethasone, triamcinolone, corticosteroid, topical, spray, vehicles, treatment, and clinical trial.
RESULTS
For moderate-to-severe plaque psoriasis, 87% of subjects achieved an Overall Disease Severity (ODS) Score ≤2 at week two and 78% achieved an ODS ≤1 after four weeks with clobetasol propionate (CP) 0.05% spray compared to 17% and 3% in the control group, respectively (P<0.001). For desoximetasone 0.25% spray, 31%-53% with moderate-to-severe psoriasis achieve Physician's Global Assessment (PGA) score ≤1 at day 28 versus 5%-18% in the vehicle spray group (P<0.01). For betamethasone dipropionate 0.05% spray, 19% with mild-to-moderate plaque psoriasis achieved an Investigator's Global Assessment (IGA) score ≤1 or a 2-grade reduction in IGA versus 2.3% in vehicle group (P≤0.001). For mild-to-severe steroid responsive inflammatory dermatoses, 64% using triamcinolone acetonide 0.2% spray achieved clear or almost clear skin at day 14 (no P value reported). Adverse events including burning, irritation, and dryness were similar across all corticosteroids.
Topics: Administration, Cutaneous; Aerosols; Dermatitis; Glucocorticoids; Humans; Inflammation; Medication Adherence; Patient Preference; Psoriasis
PubMed: 31553858
DOI: No ID Found -
Cutis Sep 2018Although topical corticosteroids are the mainstay of treatment of atopic dermatitis (AD), these medications may lose efficacy over time, a phenomenon known as... (Randomized Controlled Trial)
Randomized Controlled Trial
Although topical corticosteroids are the mainstay of treatment of atopic dermatitis (AD), these medications may lose efficacy over time, a phenomenon known as tachyphylaxis. However, the underlying mechanism for tachyphylaxis may be due to lack of treatment adherence rather than loss of efficacy of topical corticosteroids. In this study, we aimed to determine if AD patients who were previously unsuccessfully treated with topical corticosteroids would respond to desoximetasone spray 0.25% under conditions designed to promote good adherence over a 7-day period. At baseline, patients were randomized to receive either twice-daily telephone calls to discuss treatment adherence (intervention group) or no telephone calls (control group) during the study period. The patients improved rapidly. In most patients, treatment-resistant AD is most likely due to poor adherence to treatment rather than loss of drug responsiveness.
Topics: Administration, Topical; Dermatitis, Atopic; Drug Resistance; Female; Glucocorticoids; Humans; Male; Middle Aged; Treatment Failure; Treatment Outcome
PubMed: 30372711
DOI: No ID Found -
Endocrine, Metabolic & Immune Disorders... Mar 2012Glucocorticoids (GCs) have been prescribed to treat a variety of diseases, including inflammatory myopathies and Duchenne muscular dystrophy for over 50 years. However,... (Review)
Review
Glucocorticoids (GCs) have been prescribed to treat a variety of diseases, including inflammatory myopathies and Duchenne muscular dystrophy for over 50 years. However, their prescription remains controversial due to the significant side effects associated with the chronic treatment. It is a common belief that the clinical efficacy of GCs is due to their transrepression of pro-inflammatory genes through inhibition of inflammatory transcription factors (i.e. NF-κB, AP-1) whereas the adverse side effects are attributed to the glucocorticoid receptor (GR)-mediated transcription of target genes (transactivation). The past decade has seen an increased interest in the development of GR modulators that maintain the effective anti-inflammatory properties but lack the GR-dependent transcriptional response as a safe alternative to traditional GCs. Many of these analogues or "dissociative" compounds show potential promise in in vitro studies but fail to reach human clinical trials. In this review, we discuss molecular effects of currently prescribed GCs on skeletal muscle and also discuss the current state of development of GC analogues as alternative therapeutics for inflammatory muscle diseases.
Topics: Anti-Inflammatory Agents; Benzofurans; Benzopyrans; Benzoxazines; Benzylidene Compounds; Desoximetasone; Glucocorticoids; Humans; Hydroxycorticosteroids; Molecular Targeted Therapy; Myositis; Quinolines; Receptors, Glucocorticoid
PubMed: 22214335
DOI: 10.2174/187153012799279045 -
Medicinski Pregled 2012This prospective study was aimed at examining the modification of ultrasound characteristics of psoriatic plaques during desoximetasone and dithranol treatment. (Randomized Controlled Trial)
Randomized Controlled Trial
INTRODUCTION
This prospective study was aimed at examining the modification of ultrasound characteristics of psoriatic plaques during desoximetasone and dithranol treatment.
MATERIAL AND METHODS
The examination included 50 patients with chronic plaque-type psoriasis to whom 0.25% desoximetasone and dithranol was applied on the psoriatic lesions in the period of 21 days. The changes were measured before and every 7 days after the beginning of therapy by the combined application of A- and B-mode echosonography. RESULTS. At the beginning of the examination, the average values of the enter echo were 0.67 +/- 0.53 mm; hypoehogen shadow 0.30 +/- 0.11 mm, and dermis thickness 3.03 +/- 1.05 mm. On the first check up, the average values of the enter echo were 0.45 +/- 0.29 mm; hypoechogen shadow 0.23 +/- 0.08 mm and dermis thickness 2.65 +/- 0.97 mm. On the second check up, the average values of the enter echo were 0.30 +/- 0.18 mm; hypoechogen shadow 0.21 +/- 0.18 mm, dermis thickness 2.18 +/- 0.82 mm. On the third check up, the average values of the enter echo were 0.24 +/- 0.17 mm; hypoechogen shadow 0.18 +/- 0.17 mm, and dermis thickness 1.8 +/- 0.69 mm. DISCUSSION. The evaluation of the ultrasonographic characteristics revealed a significant reduction in the values in the course of the examination. Statistically significant differences were found before, during, and at the end of the examination by recording the ultrasound parameters of the epidermis and dermis and by following their modification. CONCLUSION. Precise determination of ultrasound parameters of epidermis and dermis and the possibility of recording their modification in a shorter or longer time interval can be used for monitoring and assessment of therapy effect of a medication.
Topics: Administration, Cutaneous; Anthralin; Anti-Inflammatory Agents; Dermatologic Agents; Desoximetasone; Female; Glucocorticoids; Humans; Male; Middle Aged; Psoriasis; Skin; Ultrasonography
PubMed: 23214328
DOI: 10.2298/mpns1210368s -
An open clinical trial comparing (paired comparisons) desoximetasone with betamethasone 17-valerate.The Medical Journal of Malaysia Jun 1978
Comparative Study
Topics: Betamethasone; Betamethasone Valerate; Desoximetasone; Dexamethasone; Drug Evaluation; Eczema; Humans; Psoriasis
PubMed: 732627
DOI: No ID Found -
JAMA Jan 1978
Topics: Administration, Topical; Adrenal Cortex Hormones; Cushing Syndrome; Dexamethasone; Female; Hirsutism; Humans; Middle Aged; Psoriasis
PubMed: 621843
DOI: No ID Found -
Archives of Dermatology Dec 1988
Topics: Desoximetasone; Dexamethasone; Emollients; Female; Humans; Middle Aged; Patch Tests; Photosensitivity Disorders
PubMed: 3190264
DOI: No ID Found -
Clinical Therapeutics 1985In a multicenter, investigator-blind study, desoximetasone ointment 0.25% was compared with fluocinonide ointment 0.05% in the treatment of patients with psoriasis.... (Clinical Trial)
Clinical Trial Comparative Study
In a multicenter, investigator-blind study, desoximetasone ointment 0.25% was compared with fluocinonide ointment 0.05% in the treatment of patients with psoriasis. Evaluations were made before treatment and after 4, 7, and 14 days of treatment. Both drugs were shown to be safe and effective. Desoximetasone was significantly superior to fluocinonide in improving severity scores from baseline for thickening (days 7 and 14) and erythema (day 14); in numbers of subjects cleared of thickening (day 4); in overall evaluation ratings as compared to baseline (day 14); and in number of patients receiving an overall evaluation of excellent. No side effects were reported for either treatment group during the study.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Desoximetasone; Dexamethasone; Female; Fluocinolone Acetonide; Fluocinonide; Humans; Male; Middle Aged; Ointments; Psoriasis; Random Allocation
PubMed: 3914368
DOI: No ID Found -
Drugs Oct 1978
Review
Topics: Animals; Desoximetasone; Dexamethasone; Humans; Kinetics; Skin Diseases
PubMed: 359312
DOI: 10.2165/00003495-197816040-00002 -
Acta Dermato-venereologica 1976Thirty psoriatics were treated for 2 weeks on a double-blind controlled basis with desoximetasone (0.25%) and with hydrocortisone butyrate (0.1%). It was a randomised... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
Thirty psoriatics were treated for 2 weeks on a double-blind controlled basis with desoximetasone (0.25%) and with hydrocortisone butyrate (0.1%). It was a randomised left-right comparative trial. Thirteen out of 27 patients preferred desoximetasone, 3 patients preferred hydrocortisone butyrate. There was also a significantly better effect of desoximetasone as judged by the observer after the second week of treatment.
Topics: Administration, Topical; Anti-Inflammatory Agents; Clinical Trials as Topic; Dexamethasone; Drug Evaluation; Humans; Hydrocortisone; Ointments; Psoriasis
PubMed: 60029
DOI: No ID Found